Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:ZVRA

Zevra Therapeutics Q3 2026 Earnings Date & Estimates

Zevra Therapeutics logo
$9.53 -0.28 (-2.85%)
Closing price 04:00 PM Eastern
Extended Trading
$9.52 -0.01 (-0.10%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zevra Therapeutics is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Zevra Therapeutics in Q3 2026

Zevra Therapeutics is expected to post earnings of $0.14 per share on revenue of $37.08 million. In the same quarter a year earlier Zevra Therapeutics reported -$0.01 per share on revenue of $26.06 million. Zevra Therapeutics last reported on August 5, 2026, posting $0.25 per share and beating the $0.11 consensus estimate. Zevra Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.14
Expected Revenue
$37.08 million
Prior-Year EPS
-$0.01
Prior-Year Revenue
$26.06 million
Expected Revenue Growth
+42.3%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.25 (Beat by +$0.14)
Last Quarter Revenue
$39.66 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Zevra Therapeutics Q3 2026 Earnings FAQ

Zevra Therapeutics (NASDAQ:ZVRA) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Zevra Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Zevra Therapeutics to post earnings of $0.14 per share for Q3 2026.

The consensus revenue estimate for Zevra Therapeutics is $37.08 million for Q3 2026.

Zevra Therapeutics Earnings Headlines

Analyzing Indivior (NASDAQ:INDV) & Zevra Therapeutics (NASDAQ:ZVRA)
October 24 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151784
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
October 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/20/3384268/16626/en/zevra-therapeutics-announces-details-for-q3-2026-financial-results-call.html
Why tech stocks are dead
AI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the big tech names pouring billions into data centers. Walmart's $24 million satellite network, AMR's Sabre system, and Capital One's 36,114 pricing tests all prove the same thing: compute has always been business's biggest moat, and it's about to get cheaper than ever. Porter Stansberry says one overlooked, government-protected sector is positioned to absorb this near-free compute boom and could become the next Magnificent 7.tc pixel
October 26 at 1:00 AM  |  Porter & Company (Ad)
Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal
October 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4954426-zevra-therapeutics-cash-plus-a-drug-priced-below-its-rivals-deal
Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor
October 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952147-zevra-therapeutics-miplyffa-validates-the-bull-case-europe-still-the-swing-factor
Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946250-zevra-therapeutics-inc-zvra-presents-at-morgan-stanley-24th-annual-global-healthcare
See More Zevra Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zevra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zevra Therapeutics and other key companies, straight to your email.

About Zevra Therapeutics

Zevra Therapeutics (NASDAQ:ZVRA) is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat. Niemann-Pick disease type C is a rare, progressive genetic disorder that affects the body’s ability to transport cholesterol and other lipids within cells.

The company also maintains a development pipeline targeting additional rare diseases and central nervous system conditions. Zevra was formed through the combination of Acer Therapeutics and KemPharm and is led by Chief Executive Officer Neil F. McFarlane. Its operations and commercial activities are primarily focused on the United States, with potential international opportunities for its rare-disease therapies.

View Zevra Therapeutics Profile
Earnings Tools